Analyst Viewpoint
Advancements in sequencing technologies is driving the global next generation sequencers (NGS) market. NGS technologies have emerged as a cornerstone in deciphering the complexities of genomics by enabling rapid and cost-effective sequencing of DNA and RNA. Increase in demand for personalized medicine and precision diagnostics is propelling market expansion. Furthermore, surge in funding for and awareness about advanced genomic technologies is expected to bolster the global next generation sequencers (NGS) industry size during the forecast period.
Advancements in sequencing technologies, such as improved read lengths, enhanced accuracy, and reduced costs per base pair offer lucrative opportunities to market players. Furthermore, companies are focusing on collaborations and partnerships with research institutions in order to develop more user-friendly and automated NGS platforms.
However, challenges such as data management, standardization of protocols, and ethical concerns related to genetic privacy is likely to restrain the global next generation sequencers (NGS) market in the near future.
Next Generation Sequencers (NGS) represent a breakthrough in DNA sequencing technology, offering a departure from traditional methods. NGS platforms employ highly parallelized approaches, enabling simultaneous sequencing of millions of DNA fragments. This capability results in significantly enhanced throughput, allowing for the rapid and cost-effective analysis of genetic material.
NGS technologies leverage diverse sequencing methodologies, including sequencing-by-synthesis, ion semiconductor sequencing, and single-molecule real-time sequencing. The high-throughput nature of NGS has transformed genomics research by facilitating comprehensive analyses of entire genomes, exomes, or specific target regions.
This versatility has extended applications across various domains, including basic research, clinical diagnostics, personalized medicine, and agricultural genomics.
The ongoing evolution of NGS platforms continues to improve factors such as accuracy, read length, and cost-effectiveness, establishing them as pivotal tools for unraveling the complexities of genetic information and advancing genomics research.
Next generation sequencers (NGS) has emerged as a dynamic and rapidly evolving sector within the biotechnology industry. The market has witnessed substantial growth due to the widespread adoption of NGS platforms across various research, clinical, and industrial applications.
Researchers and healthcare professionals leverage the high-throughput capabilities of NGS for diverse purposes, including genomics research, personalized medicine, clinical diagnostics, and agricultural genomics.
Advancements in sequencing technologies are driving the global next generation sequencers (NGS) market demand. Relentless pursuit of innovation in this domain has paved the way for unprecedented improvements in sequencing efficiency, accuracy, and cost-effectiveness. The evolution from traditional Sanger sequencing to state-of-the-art NGS platforms has been marked by breakthroughs in various aspects of sequencing technologies.
One pivotal advancement is the development of massively parallel sequencing techniques, enabling the simultaneous analysis of millions of DNA fragments. This parallelization has significantly expedited the sequencing process, allowing for rapid generation of large-scale genomic datasets.
Advancements in base-calling algorithms and error correction methodologies have substantially enhanced the accuracy of sequencing results. This improvement is particularly crucial in applications such as clinical diagnostics and personalized medicine, where precision is paramount.
Advent of single-molecule sequencing technologies has ushered in a new era in genomics. Technologies such as nanopore sequencing and single-molecule real-time (SMRT) sequencing offer the ability to directly read individual DNA molecules without the need for amplification. This not only reduces the risk of bias introduced during amplification, but also facilitates the detection of epigenetic modifications, providing a more comprehensive understanding of the genome.
Miniaturization and automation have played pivotal roles in advancing sequencing technologies. Development of microfluidic devices and integrated systems has led to higher throughput and reduced costs per base pair sequenced. These technological strides have made NGS more accessible across various research domains, fueling its widespread adoption.
Collectively, the market is driven by continuous advancements in sequencing technologies. The collective impact of parallelization, improved accuracy, single-molecule sequencing, and miniaturization has not only revolutionized genomic research, but has also expanded the scope of applications in fields ranging from clinical diagnostics to agriculture and beyond. As these technologies continue to mature, the next generation sequencers (NGS) market is poised for sustained growth and transformative impact on diverse scientific endeavors.
The burgeoning demand for advanced genomic technologies has stimulated a surge in funding from governmental bodies, private investors, and research institutions. This influx of financial support is instrumental in fostering research & development endeavors aimed at enhancing NGS technologies, thereby fueling innovation and expanding the next generation sequencers (NGS) market landscape.
Rise in awareness and recognition of the transformative potential of NGS technologies across diverse sectors, including healthcare, agriculture, and research, contribute significantly to market expansion.
As stakeholders become increasingly cognizant of the advantages offered by NGS, there is a rising trend of adoption in clinical diagnostics, personalized medicine, and precision agriculture. The recognition of NGS as a powerful tool for deciphering complex biological information is driving the global next generation sequencers (NGS) industry growth.
Alignment of funding initiatives with awareness campaigns creates a synergistic effect, fostering a conducive environment for market development. Initiatives that aim to educate stakeholders about the benefits and applications of NGS technologies not only enhance market penetration, but also contribute to building a robust ecosystem for continued advancements.
Collaborative efforts between industry players, research institutions, and regulatory bodies, facilitated by increased funding, promote the dissemination of knowledge and best practices. The interplay of increased funding and heightened awareness is expected to be a dynamic force propelling the next generation sequencers (NSG) market.
This symbiotic relationship not only accelerates technological advancements, but also cultivates a broader understanding of the potential applications of NGS across various domains. As financial support continues to pour into the sector and awareness campaigns gain momentum, the market is poised for sustained growth and innovation.
In terms of product, the benchtop sequencers segment accounted for the largest global next generation sequencers (NGS) market share in 2022. These devices are characterized by compact size, ease of use, and cost-effectiveness, and have emerged as the preferred choice for researchers and laboratories aiming to streamline sequencing processes.
Smaller footprint of benchtop sequencers allows for efficient utilization of laboratory space, a critical consideration in resource optimization. Additionally, these sequencers offer quicker turnaround times and lower initial investment requirements compared to their floor standing counterparts, making them more accessible to a wider range of research institutions.
Dominance of the benchtop sequencers segment can be ascribed to advancements in sequencing technologies that have empowered these compact devices to deliver high-throughput results with remarkable accuracy.
Researchers appreciate the flexibility and scalability offered by benchtop sequencers, allowing them to adapt to various experimental demands seamlessly. The user-friendly interfaces of these sequencers further contribute to their popularity, enabling researchers with diverse skill sets to efficiently operate and interpret results. Hence, benchtop sequencers have become integral to a multitude of applications, ranging from clinical diagnostics to agricultural genomics.
North America's dominance of the global next generation sequencers (NGS) market can be ascribed to several key factors. The region boasts a robust research & development infrastructure, with numerous well-established biotechnology and pharmaceutical companies leading innovation in genomics. These entities invest significantly in cutting-edge technologies, driving demand for NGS platforms.
North America also benefits from high level of government support for genomics research. Federal funding and grants contribute significantly to advancements in genomic medicine and personalized healthcare, fueling the adoption of NGS technologies. The presence of world-renowned research institutions and academic centers also plays a pivotal role in shaping the next generation sequencers (NGS) market in the region.
A mature healthcare system in North America facilitates widespread adoption of NGS in clinical settings. The region's well-developed regulatory framework ensures compliance with standards, fostering a favorable environment for the commercialization of NGS products.
Collaborations between industry players and academic institutions further accelerate the development and application of NGS technologies. This collaborative approach enhances knowledge transfer and accelerates the integration of NGS into routine clinical practices.
As per next generation sequencers (NGS) market forecast, Asia Pacific is projected to be the fastest growing region during forecast period. This is ascribed to increase in demand for personalized medicine and genomic research, bolstered by rise in awareness about the potential applications of NGS technologies.
Additionally, the region benefits from robust government initiatives and investments in genomics and biotechnology research, fostering a conducive environment for NGS market expansion.
Asia Pacific has a large and diverse population, contributing to a vast pool of genomic data that fuels research and development in the NGS sector. Collaborative efforts between academic institutions, research organizations, and industry players in the region have also played a pivotal role in advancing NGS technologies.
The region's growing healthcare infrastructure and adoption of cutting-edge technologies also contribute significantly to the escalating demand for NGS solutions, propelling Asia Pacific to the forefront of the next generation sequencers (NGS) market.
This report provides profiles of leading players operating in the global next generation sequencers (NGS) market. These players engage in mergers & acquisitions, strategic collaborations, and new product launches to expand presence and increase share.
Illumina, Inc., Thermo Fisher Scientific, Inc., Pacific Biosciences, Complete Genomics Incorporated, Vela Diagnostics, Oxford Nanopore Technologies plc, Singular Genomics Systems, Inc., HTG Molecular Diagnostics, Inc., and Revvity are the prominent players in the market.
The next generation sequencers (NGS) market report profiles the top players based on various factors including a company overview, financial summary, strategies, product portfolio, segments, and recent advancements.
Attribute | Detail |
---|---|
Size in 2022 | US$ 1.2 Bn |
Forecast (Value) in 2031 | More than US$ 2.4 Bn |
Growth Rate (CAGR) | 8.3% |
Forecast Period | 2023-2031 |
Historical Data Available for | 2017-2022 |
Quantitative Units | US$ Bn for Value |
Market Analysis | It includes segment analysis as well as regional-level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
Competition Landscape |
|
Format | Electronic (PDF) + Excel |
Segmentation |
|
Regions Covered |
|
Countries Covered |
|
Companies Profiled |
|
Customization Scope | Available upon request |
Pricing | Available upon request |
It was valued at US$ 1.2 Bn in 2022
It is projected to reach more than US$ 2.4 Bn by 2031
The CAGR is anticipated to be 8.3% from 2023 to 2031
The benchtop sequencers product segment accounted for the largest share in 2022
North America is anticipated to account for the leading share during the forecast period.
Illumina, Inc., Thermo Fisher Scientific, Inc., Pacific Biosciences, Complete Genomics Incorporated, Vela Diagnostics, Oxford Nanopore Technologies plc, Singular Genomics Systems, Inc., HTG Molecular Diagnostics, Inc., and Revvity.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Next Generation Sequencers (NGS) Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Next Generation Sequencers (NGS) Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements
5.2. Regulatory Scenario
5.3. COVID-19 Pandemic Impact on Industry
6. Global Next Generation Sequencers (NGS) Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Benchtop Sequencers
6.3.2. Floor Standing Sequencers
6.4. Market Attractiveness Analysis, by Product
7. Global Next Generation Sequencers (NGS) Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Oncology
7.3.2. Infectious Diseases
7.3.3. Reproductive Health
7.3.4. Metagenomics, Epidemiology, and Drug Development
7.3.5. Consumer Genomics
7.4. Market Attractiveness Analysis, by Application
8. Global Next Generation Sequencers (NGS) Market Analysis and Forecast, by Technology
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Technology, 2017–2031
8.3.1. WGS
8.3.2. Whole Exome Sequencing
8.3.3. Targeted Sequencing & Resequencing
8.4. Market Attractiveness Analysis, by Technology
9. Global Next Generation Sequencers (NGS) Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Academic Research
9.3.2. Clinical Research
9.3.3. Hospitals & Clinics
9.3.4. Pharma & Biotech Entities
9.3.5. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Next Generation Sequencers (NGS) Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Next Generation Sequencers (NGS) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Benchtop Sequencers
11.2.2. Floor Standing Sequencers
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Oncology
11.3.2. Infectious Diseases
11.3.3. Reproductive Health
11.3.4. Metagenomics, Epidemiology, and Drug Development
11.3.5. Consumer Genomics
11.4. Market Value Forecast, by Technology, 2017–2031
11.4.1. WGS
11.4.2. Whole Exome Sequencing
11.4.3. Targeted Sequencing & Resequencing
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Academic Research
11.5.2. Clinical Research
11.5.3. Hospitals & Clinics
11.5.4. Pharma & Biotech Entities
11.5.5. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Application
11.7.3. By Technology
11.7.4. By End-user
11.7.5. By Country
12. Europe Next Generation Sequencers (NGS) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Benchtop Sequencers
12.2.2. Floor Standing Sequencers
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Oncology
12.3.2. Infectious Diseases
12.3.3. Reproductive Health
12.3.4. Metagenomics, Epidemiology, and Drug Development
12.3.5. Consumer Genomics
12.4. Market Value Forecast, by Technology, 2017–2031
12.4.1. WGS
12.4.2. Whole Exome Sequencing
12.4.3. Targeted Sequencing & Resequencing
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Academic Research
12.5.2. Clinical Research
12.5.3. Hospitals & Clinics
12.5.4. Pharma & Biotech Entities
12.5.5. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Application
12.7.3. By Technology
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Next Generation Sequencers (NGS) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Benchtop Sequencers
13.2.2. Floor Standing Sequencers
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Oncology
13.3.2. Infectious Diseases
13.3.3. Reproductive Health
13.3.4. Metagenomics, Epidemiology, and Drug Development
13.3.5. Consumer Genomics
13.4. Market Value Forecast, by Technology, 2017–2031
13.4.1. WGS
13.4.2. Whole Exome Sequencing
13.4.3. Targeted Sequencing & Resequencing
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Academic Research
13.5.2. Clinical Research
13.5.3. Hospitals & Clinics
13.5.4. Pharma & Biotech Entities
13.5.5. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Application
13.7.3. By Technology
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Next Generation Sequencers (NGS) Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017–2031
14.2.1. Benchtop Sequencers
14.2.2. Floor Standing Sequencers
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Oncology
14.3.2. Infectious Diseases
14.3.3. Reproductive Health
14.3.4. Metagenomics, Epidemiology, and Drug Development
14.3.5. Consumer Genomics
14.4. Market Value Forecast, by Technology, 2017–2031
14.4.1. WGS
14.4.2. Whole Exome Sequencing
14.4.3. Targeted Sequencing & Resequencing
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Academic Research
14.5.2. Clinical Research
14.5.3. Hospitals & Clinics
14.5.4. Pharma & Biotech Entities
14.5.5. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Application
14.7.3. By Technology
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Next Generation Sequencers (NGS) Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product, 2017–2031
15.2.1. Benchtop Sequencers
15.2.2. Floor Standing Sequencers
15.3. Market Value Forecast, by Application, 2017–2031
15.3.1. Oncology
15.3.2. Infectious Diseases
15.3.3. Reproductive Health
15.3.4. Metagenomics, Epidemiology, and Drug Development
15.3.5. Consumer Genomics
15.4. Market Value Forecast, by Technology, 2017–2031
15.4.1. WGS
15.4.2. Whole Exome Sequencing
15.4.3. Targeted Sequencing & Resequencing
15.5. Market Value Forecast, by End-user, 2017–2031
15.5.1. Academic Research
15.5.2. Clinical Research
15.5.3. Hospitals & Clinics
15.5.4. Pharma & Biotech Entities
15.5.5. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Application
15.7.3. By Technology
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Illumina, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Thermo Fisher Scientific, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Pacific Biosciences
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Complete Genomics Incorporated
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Vela Diagnostics
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Oxford Nanopore Technologies plc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Singular Genomics Systems, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. HTG Molecular Diagnostics, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Revvity
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
List of Tables
Table 01: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 02: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 03: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 04: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 05: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 08: North America Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 09: North America Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 10: North America Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 11: Europe Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 12: Europe Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 13: Europe Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 14: Europe Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 15: Europe Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 16: Asia Pacific Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 18: Asia Pacific Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 19: Asia Pacific Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 20: Asia Pacific Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 21: Latin America Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 23: Latin America Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 24: Latin America Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 25: Latin America Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 26: Middle East & Africa Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 28: Middle East & Africa Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 29: Middle East & Africa Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 30: Middle East & Africa Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, by End-user, 2017-2031
List of Figures
Figure 01: Global Next Generation Sequencers (NGS) Market Size, by Product, 2022
Figure 02: Global Next Generation Sequencers (NGS) Market Share (%), by Product, 2022
Figure 03: Global Next Generation Sequencers (NGS) Market Size, by Application, 2022
Figure 04: Global Next Generation Sequencers (NGS) Market Share (%), by Application, 2022
Figure 05: Global Next Generation Sequencers (NGS) Market Size, by Technology, 2022
Figure 06: Global Next Generation Sequencers (NGS) Market Share (%), by Technology, 2022
Figure 07: Global Next Generation Sequencers (NGS) Market Size, by End-user, 2022
Figure 08: Global Next Generation Sequencers (NGS) Market Share (%), by End-user, 2022
Figure 09: Global Next Generation Sequencers (NGS) Market, by Region (2022 and 2031)
Figure 10: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast, 2017–2031
Figure 11: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Product, 2022 and 2031
Figure 12: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Product, 2022
Figure 13: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Product, 2031
Figure 14: Global Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Product, 2023–2031
Figure 15: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Application, 2022 and 2031
Figure 16: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Application, 2022
Figure 17: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Application, 2031
Figure 18: Global Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Application, 2023–2031
Figure 19: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Technology, 2022 and 2031
Figure 20: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Technology, 2022
Figure 21: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Technology, 2031
Figure 22: Global Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Technology, 2023–2031
Figure 23: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by End-user, 2022 and 2031
Figure 24: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by End-user, 2022
Figure 25: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by End-user, 2031
Figure 26: Global Next Generation Sequencers (NGS) Market Attractiveness Analysis, by End-user, 2023–2031
Figure 27: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Region, 2022 and 2031
Figure 28: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Region, 2022
Figure 29: Global Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Region, 2031
Figure 30: Global Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Region, 2023–2031
Figure 31: North America Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 32: North America Next Generation Sequencers (NGS) Market Value Share Analysis, by Country, 2022 and 2031
Figure 33: North America Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Country, 2023–2031
Figure 34: North America Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Product, 2022 and 2031
Figure 35: North America Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Product, 2023-2031
Figure 36: North America Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Application, 2022 and 2031
Figure 37: North America Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Application, 2023-31
Figure 38: North America Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Technology, 2022 and 2031
Figure 39: North America Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Technology, 2023-31
Figure 40: North America Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by End-user, 2022 and 2031
Figure 41: North America Next Generation Sequencers (NGS) Market Attractiveness Analysis, by End-user, 2023-2031
Figure 42: Europe Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 43: Europe Next Generation Sequencers (NGS) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 44: Europe Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 45: Europe Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Product, 2022 and 2031
Figure 46: Europe Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Product, 2023-2031
Figure 47: Europe Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Application, 2022 and 2031
Figure 48: Europe Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Application, 2023-2031
Figure 49: Europe Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Technology, 2022 and 2031
Figure 50: Europe Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Technology, 2023-2031
Figure 51: Europe Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by End-user, 2022 and 2031
Figure 52: Europe Next Generation Sequencers (NGS) Market Attractiveness Analysis, by End-user, 2023-2031
Figure 53: Asia Pacific Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 54: Asia Pacific Next Generation Sequencers (NGS) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 55: Asia Pacific Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Asia Pacific Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Product, 2022 and 2031
Figure 57: Asia Pacific Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Product, 2023-2031
Figure 58: Asia Pacific Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Application, 2022 and 2031
Figure 59: Asia Pacific Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Application, 2023-2031
Figure 60: Asia Pacific Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Technology, 2022 and 2031
Figure 61: Asia Pacific Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Technology, 2023-2031
Figure 62: Asia Pacific Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by End-user, 2022 and 2031
Figure 63: Asia Pacific Next Generation Sequencers (NGS) Market Attractiveness Analysis, by End-user, 2023-2031
Figure 64: Latin America Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 65: Latin America Next Generation Sequencers (NGS) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 66: Latin America Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 67: Latin America Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Product, 2022 and 2031
Figure 68: Latin America Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Product, 2023-2031
Figure 69: Latin America Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Application, 2022 and 2031
Figure 70: Latin America Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Application, 2023-2031
Figure 71: Latin America Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Technology, 2022 and 2031
Figure 72: Latin America Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Technology, 2023-2031
Figure 73: Latin America Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by End-user, 2022 and 2031
Figure 74: Latin America Next Generation Sequencers (NGS) Market Attractiveness Analysis, by End-user, 2023-2031
Figure 75: Middle East & Africa Next Generation Sequencers (NGS) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 76: Middle East & Africa Next Generation Sequencers (NGS) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 77: Middle East & Africa Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 78: Middle East & Africa Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Product, 2022 and 2031
Figure 79: Middle East & Africa Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Product, 2023-2031
Figure 80: Middle East & Africa Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Application, 2022 and 2031
Figure 81: Middle East & Africa Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Application, 2023-2031
Figure 82: Middle East & Africa Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by Technology, 2022 and 2031
Figure 83: Middle East & Africa Next Generation Sequencers (NGS) Market Attractiveness Analysis, by Technology, 2023-2031
Figure 84: Middle East & Africa Next Generation Sequencers (NGS) Market Value (US$ Mn) Share Analysis, by End-user, 2022 and 2031
Figure 85: Middle East & Africa Next Generation Sequencers (NGS) Market Attractiveness Analysis, by End-user, 2023-2031